EUCTR2015-002743-33-IT进行中（未招募）1 期
A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa) - Promis 1
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ZAMBON SPA
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects can be included in the trial if they meet all the inclusion criteria listed below:1)are able and willing to give informed consent, following a detailed explanation of participation in the protocol and signed consent obtained;2)are aged 18 years or older of either gender;3)diagnosed with NCFB by computerised tomography (CT) or high resolution CT (HRCT) as recorded in the subject's notes;4)had at least 2 NCFB pulmonary exacerbations requiring oral antibiotics or 1 NCFB pulmonary exacerbation requiring intravenous antibiotics in the 12 months preceding the Screening Visit (Visit 1) and had no NCFB pulmonary exacerbation with or without treatment during the period between Visit 1 and Visit 2;5)have a documented history of P. aeruginosa infection; 6) are clinically stable and have not required a change in pulmonary treatment for at least 30 days before the Screening Visit (Visit 1); 7) have pre-bronchodilator FEV1 =30% of predicted; 8) had a positive sputum culture for P. aeruginosa from an adequate sample taken at the Screening Visit (Visit 1).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 210
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 210
排除标准
- •Subjects are not eligible for the trial if they meet one or more of the exclusion criteria listed below:1)known bronchiectasis as a consequence of cystic fibrosis (CF);2)known history of hypogammaglobulinaemia requiring treatment with immunoglobulin, unless fully replaced and considered immunocompetent by the Investigator;3)myasthenia gravis, porphyria or myeloproliferative disease;4)severe cardiovascular disease such as severe uncontrolled hypertension, ischaemic heart disease or cardiac arrhythmia and any other conditions that would confound the evaluation of safety, in the opinion of the Investigator;5)had major surgery in the 3 months prior to the Screening Visit (Visit 1) or planned inpatient major surgery during the study period;6)receiving treatment for allergic bronchopulmonary aspergillosis (ABPA);7)had massive haemoptysis (greater than or equal to 300 mL or requiring blood transfusion) in the preceding 4 weeks before the Screening Visit (Visit 1) or between Visit 1 and Visit 2;8)predominant lung condition being chronic obstructive pulmonary disease (COPD), asthma or interstitial lung disease in the opinion of the Investigator;9)respiratory failure requiring long term oxygen therapy or noninvasive ventilation;10)current active malignancy, except for basal cell carcinoma of the skin without metastases;11)taking immunosuppressive medications (such as azathioprine,methotrexate, ciclosporine, tacrolimus, sirolimus, mycophenolate,rituximab), and/or anti-cytokine medications (such as anti IL-6 and antitumour alpha necrosis factor products) in the preceding year before the Screening Visit (Visit 1);12)known history of human immunodeficiency virus (HIV);13)current diagnosis or current treatment for non-tuberculous mycobacterium (NTM) pulmonary disease or Mycobacterium tuberculosis infection;14)known to be intolerant to inhaled beta-2 agonists (bronchodilators);15)known or suspected to be allergic or unable to tolerate colistimethate sodium (intravenous or inhaled) or other polymixins, including previous evidence of bronchial hyperreactivity following inhaled colistimethate sodium;16)treatment with long term (= 30 days) prednisone at a dose greater than 15 mg a day (or equivalent dose of any other corticosteroid) within six months of the Screening Visit (Visit 1);17)new maintenance treatment with oral macrolides (e.g. azithromycin/erythromycin/clarithromycin) started within 30 days of the Screening Visit (Visit 1) and between Visit 1 and Visit 2;18)use of any intravenous or intramuscular or oral or inhaled antipseudomonal antibiotic (except chronic oral macrolide treatment with a stable dose) within 30 days prior to the Screening Visit (Visit 1);19)pregnant or breast feeding or plan to become pregnant over the next year or of child-bearing potential and unwilling to use a reliable method of contraception for at least one month before randomisation and throughout their involvement in the trial;20)significant abnormality in clinical evaluations and/or laboratory tests (physical examination, vital signs, haematology, clinical chemistry, clinically relevant impaired renal function, defined as serum creatinine levels =2.0x upper limit of normal, ECG) endangering the safe participation of the patient in the study at the Screening Visit (Visit 1)and during the study;21)participated in another investigational, interventional trial within 30 days prior to the Screening Visit (Visit 1);22)in the opinion of the Investigator not suitable for inclu
研究者
相似试验
进行中（未招募）
1 期
A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)on-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosaMedDRA version: 21.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002743-33-PTZambon S.p.A.377
已完成
3 期
A double-blind, placebo-controlled, multi-centre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)NL-OMON48850Zambon SpA10
进行中（未招募）
1 期
A clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)on-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosaMedDRA version: 21.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002743-33-DEZambon S.p.A.420
进行中（未招募）
1 期
A clinical trial to investigate the efficacy and safety of inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)EUCTR2015-002743-33-NLZambon S.p.A.420
进行中（未招募）
1 期
A clinical trial to investigate the efficacy and safety of inhaled colistimethate sodium in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P. aeruginosa)on-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosaMedDRA version: 21.0Level: PTClassification code 10006445Term: BronchiectasisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-002743-33-GRZambon S.p.A.420